XML 58 R35.htm IDEA: XBRL DOCUMENT v3.25.4
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Common Shares
As of each balance sheet date, common shares consisted of the following:
December 31, 2024December 31, 2025
Shares authorizedShares issued and outstandingShares authorizedShares issued and outstanding
Common sharesUnlimited295,757,002Unlimited300,600,710
Schedule of Stock Option Activity
The following table summarizes the Company’s stock options granted under the Pre-IPO Plan:
Number of
Shares		Weighted-
Average Exercise
Price		Weighted-
Average Contractual Term (years)
Outstanding as of December 31, 202426,732,456$0.99 4.30
Granted—— 
Exercised(2,643,237)0.22 
Forfeited0— 
Outstanding as of December 31, 202524,089,219$1.07 3.60
Options exercisable as of December 31, 202524,089,219$1.07 3.60

The following table summarizes the Company’s stock options granted under the 2020 Plan:
Number of
Shares		Weighted-
Average Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (years)
Outstanding as of December 31, 202424,008,664$9.93 8.11
Granted14,576,2413.05 
Exercised(52,067)4.62 
Forfeited(2,156,797)6.50 
Outstanding as of December 31, 202536,376,041$7.38 7.76
Options exercisable as of December 31, 202515,877,440$11.46 6.61
Schedule of Restricted Share Units Activity
The following table summarizes the Company’s RSUs granted under the 2020 Plan:
 
Number of Shares
Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 20246,629,833$7.53 
Granted5,302,7623.12 
Vested and settled(2,148,404)9.12 
Forfeited(946,807)5.22 
Outstanding as of December 31, 20258,837,384$4.75 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense was classified in the consolidated statements of loss and comprehensive loss as follows:
Year ended December 31,
202320242025
Research and development expenses$31,781 $30,779 $30,147 
Sales, general, and administrative expenses32,403 36,802 25,645 
$64,184 $67,581 $55,792 
Schedule of Valuation Assumptions
The fair value of each option award is determined on the date of grant using the Black-Scholes option pricing model. The weighted-average valuation assumptions for stock options granted in the period are as follows:

Year ended December 31,
202320242025
Average risk-free interest rate1
3.73 %3.94 %4.41 %
Expected volatility2
70.0 %70.0 %70.0 %
Average expected term (years)3
6.256.226.20
Expected dividend yield4
0.0 %0.0 %0.0 %
Weighted average fair value of options granted5
$5.78 $3.42 $2.04 
(1)This rate is from federal government marketable bonds for each option grant during the year, having a term that most closely resembles the expected term of the option.
(2)Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar complexity and stage of development and calculates historical volatility using the volatility of these companies.
(3)This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses the simplified method to calculate the average expected term, which represents the average of the vesting period and the contractual term.
(4)No dividends are expected to be paid by the Company.
(5)Options are granted with an exercise price equal to the fair market value of the Company’s common stock on the grant date.